Navigation Links
Logical Therapeutics Secures $16.9M Series C Financing Round
Date:5/26/2010

Lead Candidate, LT-NS001, Shows Evidence of Improved GI Safety for Arthritis Patients

WALTHAM, Mass., May 26 /PRNewswire/ -- Logical Therapeutics, Inc., a private, clinical stage biopharmaceutical company, announced today it had closed on a $16.9 million Series C equity financing.  The round was led by existing investor SV Life Sciences, and included Burrill & Company, Novo A/S and Novitas Capital.

Logical Therapeutics is developing a family of new chemical entities using its patented Bio-activated Technology.TM The proprietary platform, which modifies the chemical structure of NSAIDs (non-steroidal anti-inflammatory drugs), is being developed to significantly reduce the gastrointestinal (GI) side effects often associated with NSAIDs.  The Company's lead compound, LT-NS001 (naproxen etemesil), is currently being studied in a Phase 2b/3 study comparing the cumulative rate of gastric ulcers vs. Naprosyn® in osteoarthritis patients after 12 weeks of treatment.  Completion of the study is expected in late 2010.

The Series C financing round is expected to provide sufficient capital to advance the Company's development program through further clinical and non-clinical activities necessary for registration. The Company intends to seek a business partner prior to commercialization.  

About Logical Therapeutics, Inc.

Based in Waltham, MA, Logical Therapeutics, Inc. is a venture-backed, privately held biopharmaceutical company focused on the development of bio-activated prodrugs to treat inflammatory conditions such as osteoarthritis and rheumatoid arthritis.  The Company's Bio-activated TechnologyTM has created a portfolio of molecules including LT-NS001, a naproxen prodrug and several additional bio-activated NSAID prodrug candidates, which are covered by issued and pending U.S. and international patents.  Each program addresses unmet medical needs in multi-billion dollar markets.  For more information about Logical Therapeutics, visit the Company's website at www.logicaltx.com.

LT-NS001 is an investigational drug product candidate undergoing clinical evaluation and has not been approved by the U.S. Food and Drug Administration.

Bio-activated TechnologyTM is a trademark of Logical Therapeutics, Inc.


'/>"/>
SOURCE Logical Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
2. Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
3. Neurobiological Technologies Announces Filing of Certificate of Dissolution and Closing of Stock Transfer Books
4. Tuesday, Dec. 1: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
5. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
6. Monday, Nov. 30: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
7. Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago
8. China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
9. Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
10. Reportlinker Adds Audiological Devices - Global Market Trends
11. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):